MECHANISMS OF SYNERGISTIC ANTILEUKEMIC INTERACTIONS BETWEEN VALPROIC ACID AND CYTARABINE IN PEDIATRIC ACUTE MYELOID LEUKEMIA

Chengzhi Xie\textsuperscript{1,2}, Holly Edwards\textsuperscript{1}, Xuelian Xu\textsuperscript{1,2}, Hui Zhou\textsuperscript{2}, Steven A. Buck\textsuperscript{3}, Mark L. Stout\textsuperscript{3}, Qun Yu\textsuperscript{4}, Jeffrey E. Rubnitz\textsuperscript{5}, Larry H. Matherly\textsuperscript{1,6,7}, Jeffrey W. Taub\textsuperscript{1,3,8}, and Yubin Ge\textsuperscript{1,2,7,8}

\textsuperscript{1}Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, \textsuperscript{2}College of Life Science, Jilin University, Changchun, P.R.China, \textsuperscript{3}Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI, \textsuperscript{4}Beijing Institute of Transfusion Medicine, Beijing 100850, P.R.China, \textsuperscript{5}Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, Departments of \textsuperscript{6}Pharmacology, \textsuperscript{7}Oncology, and \textsuperscript{8}Pediatrics, Wayne State University School of Medicine, Detroit, MI

Running title: Synergisms between valproic acid and cytarabine in pediatric AML

Address correspondence and reprint requests:

Yubin Ge, Ph.D.
Developmental Therapeutics Program
Karmanos Cancer Institute
110 East Warren Ave.
Detroit, Michigan 48201, USA
(313) 578-4285
FAX: (313) 578-4287
gey@karmanos.org

Abstract: 248 words
Text: 4011 words
STATEMENT OF TRANSLATIONAL RELEVANCE

In this study, we demonstrate highly synergistic antileukemic activities of combined cytarabine (ara-C) and VPA in a panel of pediatric AML cell lines and diagnostic blast samples derived from children with de novo AML. Thus, VPA could be an attractive agent for combination therapy for children with this deadly disease. Based on our results, VPA was recently incorporated into one of the treatment arms for high risk AML in the St. Jude Children’s Research Hospital AML08 clinical trial “A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia”. In this trial, children with AMkL without t(1;22) and other high risk patients without FLT3-ITD will receive a combination of VPA with low dose ara-C, daunorubicin and etoposide (LD-ADE) during the second induction course.
ABSTRACT

Purpose: To determine the possibility of synergistic anti-leukemic activity and the underlying molecular mechanisms associated with cytarabine combined with valproic acid (VPA) [a histone deacetylase inhibitor (HDACI) and an FDA-licensed drug for treating both children and adults with epilepsy] in pediatric acute myeloid leukemia (AML).

Experimental Design: The type and extent of anti-leukemic interactions between cytarabine and VPA in clinically relevant pediatric AML cell lines and diagnostic blasts from children with AML were determined by MTT assays and standard isobologram analyses. The effects of cytarabine and VPA on apoptosis and cell cycle distributions were determined by flow cytometry analysis and caspase enzymatic assays. The effects of the two agents on DNA damage and Bcl-2 family proteins were determined by Western blotting.

Results: We demonstrated synergistic antileukemic activities between cytarabine and VPA in 4 pediatric AML cell lines and 9 diagnostic AML blast samples. t(8;21) AML blasts were significantly more sensitive to VPA and showed far greater sensitivities to combined cytarabine and VPA than non-t(8;21) AML cases. Cytarabine and VPA cooperatively induced DNA double strand breaks, reflected in induction of γH2AX and apoptosis, accompanied by activation of caspases 9 and 3. Further, VPA induced Bim expression and shRNA knockdown of Bim resulted in significantly decreased apoptosis induced by cytarabine, and by cytarabine plus VPA.

Conclusions: Our results establish global synergistic antileukemic activity of combined VPA and cytarabine in pediatric AML and provide compelling evidence to support the use of VPA in the treatment of children with this deadly disease.
INTRODUCTION

Acute myeloid leukemia (AML) accounts for one-fourth of acute leukemias in children, but it is responsible for more than half of the leukemia deaths in this patient population.\(^1\) In contrast to the tremendous success in treating acute lymphoblastic leukemia over the last three decades, resulting in a >80% cure rate, improvements in AML therapy have been limited\(^1\). Resistance to cytarabine, the most active drug in the treatment of AML, is a major cause of treatment failure.\(^2,3\) Therefore, new therapies for children with AML are urgently needed.

Cytarabine is a prodrug that must be converted to a triphosphate derivative (ara-CTP) to exert its cytotoxic effects.\(^4\) Cytarabine cytotoxicity is believed to result from a combination of DNA polymerase inhibition and incorporation of ara-CTP into DNA, resulting in chain termination and a blockade of DNA synthesis.\(^4\) In addition, previous studies have documented the ability of cytarabine to trigger apoptosis in human leukemia cells.\(^4\)

Histone deacetylase (HDAC) inhibitors (HDACIs) promote histone acetylation and subsequent chromatin relaxation and uncoiling, which facilitates transcription of different genes, especially those involved in cellular differentiation.\(^5\) HDACIs may also disrupt the function of HDACs in co-repressor complexes implicated in the differentiation blockade exhibited by certain forms of AML [e.g., t(8;21) AML and APL involving t(15;17)].\(^6,7\) HDACI cytotoxicity is regulated by diverse mechanisms including activation of stress-related pathways or inactivation of cytoprotective pathways, up-regulation of death receptors, induction of p21\(^{CIP1}\), ceramide production, disruption of heat shock proteins, and induction of oxidative damage.\(^8\) Further, emerging evidence suggests that HDACIs can directly induce DNA damage in leukemia cells.\(^9\) A number of HDACIs are currently being tested in clinical trials and encouraging results have been reported for their use in treating both hematological malignancies and solid tumors.\(^10-16\)
However, no HDACIs have yet been approved by the US Food and Drug Administration (FDA) for treating children with cancer.

Recently, the anticonvulsant drug valproic acid (VPA) was reported to exhibit powerful HDACI activity,\textsuperscript{17,18} and to induce apoptosis in leukemia cells but not in normal cells at clinically achievable concentrations (100-150 $\mu$g/ml).\textsuperscript{18-20} VPA is usually well tolerated in children and the extensive clinical experience with this drug makes it a very attractive agent for treating pediatric AML. In fact, preclinical and clinical studies have demonstrated additive-to-synergistic antileukemic effects on AML when VPA is used in combination with other chemotherapy agents including idarubicin,\textsuperscript{21} 5-aza-2’-deoxycytidine,\textsuperscript{22} gemtuzumab ozogamicin,\textsuperscript{23} and NPI-0052.\textsuperscript{24} Recently, VPA was reported to markedly increase cytarabine cytotoxicity in a single AML cell line.\textsuperscript{25} However, neither the mechanisms of interaction between VPA and cytarabine nor the extent to which these results can be generalized to different AML subtypes have been established.

In this study, we hypothesize that VPA synergizes with cytarabine, resulting in enhanced antileukemic activity in AML cells, by inducing apoptosis. To model this concept, we examined the impact of VPA on cytarabine cytotoxicities in 4 pediatric AML cell lines and 9 diagnostic blast samples from children with \textit{de novo} AML. We demonstrate highly synergistic antileukemic activities of combined cytarabine and VPA in all of the cell lines and diagnostic blast samples, especially those with t(8;21). Our mechanistic studies reveal cooperative induction of DNA damage by cytarabine and VPA and induction of Bim by VPA that underlie the synergistic activity of this drug combination. Collectively, our results provide compelling evidence to support the use of VPA in combination with standard chemotherapy drugs in clinical trials for treating pediatric AML.
MATERIAL AND METHODS

Clinical Samples

Diagnostic bone marrow samples (n=9) from children with *de novo* AML were obtained from the Children’s Hospital of Michigan leukemia cell bank. Cell bank samples were selected from cases with sufficient cell numbers (minimum 5 x 10^6, blast percentage >75%, viability >85%). Patient characteristics are summarized in supplementary Table S1. Mononuclear cells were purified by standard Ficoll-Hypaque density centrifugation. Informed consent was provided according to the Declaration of Helsinki. Sample handling and data analysis protocols were approved by the Human Investigation Committee of the Wayne State University School of Medicine.

Drugs

Cytarabine and VPA were purchased from Sigma Chemical Company (St Louis, MO).

Cell Culture

The THP-1 [derived from a 1-year-old male with AML M5 and t(9;11)], Kasumi-1 [derived from a 7-year-old male with AML M2 and t(8;21)], and MV4-11 [derived from a 10-year-old male with AML M5 and t(4;11)] pediatric AML cell lines were purchased from American Type Culture Collection (Manassas, VA). The CMS (derived from a 2-year-old female with AML M7) pediatric AML cell line was a gift from Dr. A Fuse from the National Institute of Infectious Diseases, Tokyo, Japan. These cell lines were cultured in RPMI 1640 with 10-20% fetal bovine serum (Hyclone, Logan, UT) and 2 mM L-glutamine, plus 100 U/ml penicillin and 100 µg/ml streptomycin, in a 37 °C humidified atmosphere containing 5% CO₂/95% air.
**In Vitro Cytotoxicity Assays**

*In vitro* cytarabine and VPA cytotoxicities of pediatric AML cell lines and diagnostic blasts were measured by using MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium-bromide, Sigma) assays, as previously described. IC_{50} values were calculated as drug concentrations necessary to inhibit 50% proliferation compared to untreated control cells. The extent and direction of cytarabine and VPA cytotoxic interactions were evaluated as described previously. Briefly, synergism, additivity or antagonism was quantified by determining the combination index (CI), where CI<1, CI=1, and CI>1 indicate synergistic, additive, and antagonistic effects, respectively. Based on the classic isobologram, the CI was calculated using the following equation: CI=[(D)1/(Dx)1] + [(D)2/(Dx)2]. At the 50% inhibition level, (Dx)1 and (Dx)2 are concentrations of cytarabine and VPA, respectively, which induce a 50% inhibition in cell proliferation when administered individually. (D)1 and (D)2 are concentrations of cytarabine and VPA, respectively, which inhibit cell proliferation by 50% when combined.

**Assessment of Baseline and Drug Induced Apoptosis**

Diagnostic AML blasts from patient 7 [46, XY, t(8;21)], THP-1, and Kasumi-1 cells cultured in RPMI1640 plus 10-20% FBS were treated with VPA (0.5, 0.66, and 0.5 mM, respectively) or cytarabine (1000, 900, and 100 nM, respectively) alone or in combination for 24 h (for the patient sample) or 96 h (for the cell lines). The VPA and cytarabine doses for the cell lines were IC_{20}s, while those for patient AML blasts were ~IC_{50}s, determined by MTT assays. The same concentrations of VPA and cytarabine were used in the rest of the studies unless specified. The cells were harvested, vigorously pipetted and triplicate samples taken to determine baseline and drug-induced apoptosis using the Apoptosis Annexin-V fluorescein isothiocyanate (FITC)/propidium iodide (PI) Kit (Beckman Coulter; Brea, CA), as previously described.
Apoptotic events were recorded as a combination of Annexin-V+/PI- (early apoptotic) and Annexin-V+/PI+ (late apoptotic/dead) events and results were expressed as percent of Annexin-V+ cells after subtracting results for untreated cells. Synergy was quantified using the cooperativity index (cooperativity index = sum of apoptosis of single agent treatment/apoptosis upon combined treatment). Cooperativity index <1, =1, or >1 is termed synergistic, additive, or antagonistic, respectively.23

Effects of VPA and Cytarabine on Cell Cycle Progression in AML Cells

THP-1 or Kasumi-1 cells were treated with VPA or cytarabine alone or in combination for 96 h. Cells were harvested and fixed with ice-cold 70% (v/v) ethanol for 24 h. After centrifugation at 200 x g for 5 min, the cell pellets were washed with PBS (pH 7.4) and resuspended in PBS containing PI (50 µg/ml), Triton X-100 (0.1%, v/v), and DNase-free RNase (1 µg/ml). DNA contents were determined by flow cytometry using a FACScan flow cytometer (BD Biosciences, San Jose, CA). Cell cycle analysis was performed with the Multicycle software (Phoenix Flow Systems Inc, San Diego, CA).

Western Blot Analysis

Extracted or immunoprecipitated proteins were subjected to SDS-polyacrylamide gel electrophoresis. Separated proteins were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (Thermo Fisher Inc., Rockford, IL) and immunoblotted with anti-acetyl-histone 3 (ac-H3), -ac-H4, -H4 (Upstate Biotechnology, Lake Placid, NY), -Bak, -Bax, -Bid, -Bim, -Bad, -Puma, -p21, -Bcl-2, -Bcl-xL, -Mcl-1, -γH2AX (Cell Signaling Technology, Danvers, MA), or -β-actin (Sigma, St Louis, MO) antibody, as described previously.30 Immunoreactive proteins were visualized using the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE), as described by the manufacturer.
Caspase-9 and Caspase-3 Assays

THP-1 and Kasumi-1 cells were treated with cytarabine or VPA alone or combined for up to 96 h. Caspase-3 and caspase-9 enzymatic activities were assayed using the Caspase-3 Fluorometric Kit and the Caspase-9 Colorimetric Kit, respectively, purchased from R&D Systems (Minneapolis, MN), based on the manufacturer’s instructions. THP-1 and Kasumi-1 cells treated with 500 and 1000 nM daunorubicin, respectively, for 16 h (results in >70% apoptosis) were used as positive controls.

shRNA Knockdown of Bim in THP-1 Cells

Bim shRNA lentivirus clones were purchased from the RNAi Consortium (Sigma-Aldrich). THP-1 cells were infected by shRNA lentivirus clones. After selection with puromycin, a pool of infected cells was expanded and tested for Bim expression by Western blotting (designated Bim-shRNA). A pool of cells from the negative control transduction was used as the negative control (designated NTC-shRNA).

Statistical Analysis

Differences in cytarabine IC₅₀s between VPA treated and untreated AML cells and differences in cell apoptosis between cytarabine and VPA treated (individually or combined) and untreated cells were compared using the paired t-test. The relationship between the levels of γH2AX and caspase-3 activities was determined by the Pearson test. Statistical analyses were performed with GraphPad Prism 4.0.
RESULTS

Synergistic Antileukemic Interactions between Cytarabine and VPA in Pediatric AML Cell Lines and Diagnostic Blasts

To explore the possibility of synergistic cytotoxicity when cytarabine was combined with HDACIs to treat pediatric AMLs, we tested VPA [a short-chain fatty acid HDACI which inhibits class I and class IIa HDACs5] with cytarabine toward THP-1 AML cells using MTT assays. In vitro incubation of THP-1 cells with VPA alone resulted in inhibition of cell proliferation with an IC50 of 2.97 mM (Figure 1A). This was accompanied by hyperacetylation of histones H3 and H4, but not total histone H4 (Figure 1B). This VPA concentration was in excess of the maximally achievable plasma concentration in children (1 mM), at which there was only modest inhibition of cell proliferation (Figure 1A). When simultaneously administered with cytarabine, VPA at 0.5 and 1 mM significantly enhanced cytarabine sensitivity [as reflected in decreased IC50s] by 2.1- and 4.3-fold, respectively (Figure 1C). The combined effects of cytarabine with VPA on cell proliferation were clearly synergistic, as determined by standard isobologram analysis (Figure 1D) and by calculating CI values.28 A CI<1, indicative of synergism, was calculated for each of the drug combinations (Table 1).

To determine whether the synergistic antileukemic activity of VPA and cytarabine was unique to the THP-1 subline, analogous cytotoxicity experiments were performed with the Kasumi-1, MV4-11, and CMS sublines derived from children with different AML subtypes. VPA showed variable cytotoxicities in the 3 additional AML sublines, with IC50s ranging from 0.37 to 2.7 mM (Table 1). It is interesting that MV4-11 [harbors t(4;11)] and Kasumi-1 [harbors t(8;21)] cells were both substantially more sensitive to VPA than were the THP-1 and CMS sublines (Table 1). At 0.3 mM VPA, simultaneous treatment with cytarabine resulted in 8.4- and...
34.3-fold decrease in cytarabine IC50s, respectively, in Kasumi-1 and MV4-11 cells, compared to that from cytarabine alone (Table 1). The results with the MV4-11 cells are particularly interesting since they harbor a FLT3 ITD in addition to t(4;11).31 For CMS cells, simultaneous administration of VPA and cytarabine also resulted in 2-fold decreased cytarabine IC50 at 1 mM VPA, compared to that from cytarabine alone (Table 1).

Analogous results were obtained when AML blasts collected at diagnosis from 9 children with de novo AML were evaluated following co-treatment with cytarabine and VPA (0.15 to 1 mM) (Table 1). As with Kasumi-1 cells, diagnostic blasts from t(8;21) AML cases (n=3, patients 7-9) were significantly more sensitive to VPA than non-t(8;21) AML blasts (n=6, patients 1-6) (median VPA IC50 0.38 mM vs 1.41 mM, p=0.024, Table 2 and Figure 1E) and showed 6.5- to 64.1-fold decreased cytarabine IC50s when combined with VPA at doses 0.5 mM or lower, compared to that from cytarabine alone. By contrast, non-t(8;21) AML blasts only showed 1.3- to 13-fold decrease in cytarabine IC50s when combined with 0.5 mM VPA (p=0.024, Table 2 and Figure 1F).

For both AML cell lines and diagnostic blast samples, cytarabine and VPA were again synergistic by isobologram analyses (not shown) and by CI values (Table 1). Collectively, our results demonstrate that synergistic antileukemic effects of combined cytarabine and VPA are broad-ranging and occur in multiple AML subtypes.

VPA and Cytarabine Synergistically Induce Apoptosis of Pediatric AML Cells

We hypothesized that VPA may lower the apoptotic threshold in pediatric AML cells, rendering them more susceptible to apoptosis induced by cytarabine. Another possibility could be that VPA combines with cytarabine to induce cell cycle arrest, resulting in synergistic antileukemic activity on this basis. To test these hypotheses, THP-1 and Kasumi-1 cells, treated...
with cytarabine and VPA individually or in combination for 96 h, were analyzed by flow cytometry to determine impacts on cell cycle distribution and apoptosis. Treatment with cytarabine alone substantially induced apoptosis in both THP-1 and Kasumi-1 cells, while treatment with VPA by itself resulted in only marginally increased apoptosis in both cell lines (Figures 2A and 2B). Combined VPA and cytarabine caused a substantial and synergistic induction of apoptosis compared to that resulting from the individual drug treatments (cooperativity index = 0.46 and 0.55, respectively, Figures 2A and 2B).

As expected, treatment of THP-1 and Kasumi-1 cells with cytarabine alone resulted in S phase and G2/M phase blockade compared to untreated cells (Figures 2C and 2D). Treatment with VPA by itself caused arrest in G1/S progression in THP-1 cells (Figure 2C). However, VPA treatment of Kasumi-1 cells caused at most marginal effects on cell cycle progression (e.g. slight increase of G1 phase and slight decrease of S phase) (Figure 2D). In both cell lines, co-treatment with VPA and cytarabine resulted in additional S arrest compared to that from cytarabine alone; in THP-1 cells, combined treatment resulted in an abrogation of the G1 arrest by VPA alone (Figures 2C and 2D). These results demonstrate that VPA augments both apoptosis and S phase arrest induced by cytarabine in THP-1 and Kasumi-1 cells.

To extend these latter results to diagnostic AML patient samples, blasts from patient 7 (Table 1) for which there were sufficient cells were treated with cytarabine and VPA individually or in combination for 24 h and analyzed by flow cytometry for apoptosis and cell cycle distribution. Again, there was a synergistic induction of apoptosis by combined cytarabine and VPA (cooperativity index = 0.82, Figure 2E). Changes in cell cycle distribution in the blasts could not be determined due to lack of cell proliferation (not shown).
Cytarabine and VPA Synergistically Activate Caspases 9 and 3 Pediatric AML Cells

To determine if apoptosis induced by cytarabine and VPA was associated with caspase activation, THP-1 and Kasumi-1 cells treated with cytarabine and VPA alone or combined for 96 h were subjected to caspase-9 and caspase-3 enzymatic assays. In Figure 3, co-treatments with cytarabine and VPA resulted in synergistic activation of caspases 9 and 3 in both cell lines. These results demonstrate that cytarabine and VPA synergistically induce apoptosis of pediatric AML cells through the intrinsic apoptotic pathway.

VPA and Cytarabine Cooperatively Induce DNA Damage in THP-1 and Kasumi-1 Cells

Efforts were then undertaken to determine the molecular mechanisms that underlie the synergistic induction of apoptosis by the two agents. Cytarabine is a DNA damaging agent which causes DNA double strand breaks. A previous study suggested that HDACIs can also cause DNA damage in leukemia cells.9 Thus, we hypothesized that cytarabine and VPA cooperate in causing DNA damage, which subsequently triggers apoptosis. To test this possibility, THP-1 and Kasumi-1 cells were treated with variable concentrations of cytarabine or VPA, alone or combined for 96 h, and protein lysates were subjected to Western blotting to detect γH2AX, a biomarker of DNA double strand breaks.32 Interestingly, co-treatment with VPA and cytarabine resulted in distinctly cooperative induction of γH2AX in both cell lines (Figure 4A). In Kasumi-1 cells, this cooperative induction of γH2AX was both cytarabine and VPA concentration dependent (Figure 4B). These results establish that VPA augments cytarabine-induced DNA double strand breaks which may trigger apoptosis. It is important to note that there was no difference in the extent of synergy of VPA (0.5 mM) with 100 or 200 nM cytarabine in terms of triggering DNA damage. This suggests that combing the two agents would allow for a dose reduction in cytarabine.
Induction of γH2AX by combined VPA/cytarabine was an early molecular event in Kasumi-1 cells, as revealed by a time course study (Figure 4C). Thus, substantial induction of γH2AX (2.6-fold increase relative to control) was detected by Western blotting as early as at 1.5 h (Figure 4C), accompanied by caspase-3 activation starting at 6 h (Figure 4D). Further, the levels of γH2AX significantly correlated with caspase-3 activities over 48 h ($r = 0.90$, $p = 0.06$, Figure 4E). However, this association was abolished when the 96 h time data were included ($r = 0.68$, $p = 0.06$, Figure 4F). These results strongly suggest that DNA damage was associated with caspase-3 activation in Kasumi-1 cells treated with combined cytarabine and VPA during early times (within 48 h). There may be other factor(s) contributing to the late time (96 h) caspase-3 activation in this experiment.

**Bim is a Critical Determinant of Apoptosis Induced by Cytarabine and Combined VPA and Cytarabine in Pediatric AML Cells**

Previous studies showed that HDACIs can induce Bim to promote apoptosis in cancer cells.33,34 It is conceivable that VPA also induces Bim expression in pediatric AML cells, thus contributing to apoptosis induced by combined VPA and cytarabine. As shown in Figures 5A and 5B, modest induction of the BimEL isoform by VPA and VPA plus cytarabine was detected in both THP-1 and Kasumi-1 cells. In contrast, levels for other Bel-2 family proteins were largely unchanged (Supplementary Figure S1). These results suggest that Bim could be another important determinant for the antileukemic activities of combined VPA/cytarabine in pediatric AML cells. In contrast to the DNA damage response, induction of Bim appeared to be a later molecular event in both sublines (post 48 h treatment, Figure 5C). This could explain the disproportionately increased caspase-3 activation seen at later times in Kasumi-1 cells (48 h and 96 h, Figure 4D).
To provide direct evidence that Bim is a critical effector of the antileukemic activities of cytarabine with and without VPA, lentivirus shRNA knockdown of Bim was performed in THP-1 cells. shRNA knockdown of Bim (~40%) substantially abolished its induction by VPA and combined VPA/cytarabine (Figure 5D). This was accompanied by significantly decreased apoptosis induced by cytarabine alone and combined cytarabine/VPA (Figure 5E).

Collectively, these results strongly support our hypothesis that cytarabine and VPA cause DNA double strand breaks in a cooperative fashion, which in turn triggers caspase activation and apoptosis. Further, VPA induces expression of Bim which promotes apoptosis induced by cytarabine.
DISCUSSION

HDAC inhibition represents one of the most promising epigenetic treatments for cancer because HDACIs have been established to reactivate silenced genes and exert pleiotropic antitumor effects selectively in cancer cells. The ability of HDACIs to induce cell differentiation, cell cycle arrest, and apoptosis in human leukemic cells but not in normal cells has stimulated significant interest in clinical applications as anti-leukemic agents. Currently, HDACIs including the anti-epileptic agent VPA are being evaluated in the treatment of acute leukemias. Despite their well-characterized molecular and cellular effects, single-agent activity of this class of drugs has been modest. Accordingly, there has been significant interest in developing rationally designed combination therapies using HDACIs.

In this study, we analyzed the cellular and molecular effects of combined cytarabine and VPA in a panel of clinically relevant pediatric AML cell lines and diagnostic blasts from children with de novo AML. Our rationale was based on the central role of cytarabine in AML chemotherapy and on the documented ability of VPA to induce apoptosis specifically in leukemia cells, without causing proliferation inhibition of normal hematopoietic progenitor cells. Indeed, phase I/II studies using VPA as a single agent for adults with refractory AML or myelodysplastic syndrome have shown that VPA is well tolerated.

The activity of VPA alone or in combination with cytarabine was initially evaluated against THP-1 AML cells, the most cytarabine resistant subline tested in our study. In vitro incubations of THP-1 cells with VPA resulted in inhibition of cell proliferation in a dose-dependent manner, accompanied by hyperacetylation of histones H3 and H4. Interestingly, when VPA was incubated simultaneously with cytarabine, there was a synergistic loss of cell proliferation. When this was expanded to include three additional cell lines derived from children...
with different AML subtypes, synergism was again demonstrated, suggesting that this mechanism may be broadly applicable to pediatric AMLs. Further, synergistic interactions between VPA and cytarabine were observed in 9 diagnostic blast samples from children with AML. Of particular interest, t(8;21) AML cells were significantly more sensitive to VPA and showed the greatest response to co-treatment with cytarabine and VPA. This was not unexpected, given that several fusion proteins (AML-1/ETO, PML-RARA, etc) recruit nuclear co-repressor complexes (which contain HDACs)\(^7\). Thus AML cases harboring these fusion genes might be preferentially susceptible to HDACIs. Previous pharmacokinetic studies have shown that clinically achievable trough levels of VPA used in the treatment of children with epilepsy\(^{37}\) approximate the \textit{in vitro} concentrations of VPA that synergized with cytarabine in our study.

The synergistic cytotoxicity of combined cytarabine and VPA is clearly due to cell death since synergistic induction of apoptosis by the two agents in both pediatric AML cell lines and diagnostic blasts was detected. In THP-1 cells, VPA inhibited cell cycle progression at G1/S, which may block apoptosis mediated by the HDAC1.\(^{38}\) Interestingly, combined cytarabine and VPA completely abolished VPA-induced G1 arrest and resulted in additional S phase arrest, which may favor apoptosis induced by co-treatment with these agents.

Our mechanistic studies in THP-1 and Kasumi-1 cells suggested that induction of apoptosis through caspase activation directly contributed to the potent synergism between cytarabine and VPA. Interestingly, this was accompanied by cooperative induction of DNA double strand breaks, as reflected by the induction of \(\gamma\text{H2AX}\). Induction of \(\gamma\text{H2AX}\) was significantly associated with caspase-3 activation, suggesting that DNA double strand breaks were responsible for the apoptotic response upon treatment with the two agents. However, the molecular mechanism(s) underlying VPA-induced DNA damage in pediatric AML cells remains
elusive. Additional studies are underway to further determine the effects of HDACIs in inducing DNA damage in this disease.

Besides induction of DNA damage, both VPA and combined VPA/cytarabine also induced expression of the BH3-only pro-apoptotic protein, Bim, in both Kasmui-1 and THP-1 cells. Bim has been classified as an “activator” in view of its purported ability to engage directly and activate Bax and Bak.\(^{39}\) It has been well documented that Bim is critical for HDACI-induced apoptosis of both solid tumor and leukemia cells.\(^{33,34}\) In this study, we demonstrated that Bim also plays critical roles in cytarabine and cytarabine plus VPA induced apoptosis in pediatric AML cells. However, Bim may not be responsible for the synergy between the two agents since only VPA, but not cytarabine, induced Bim expression in our experiments.

Together, our results document global synergistic antileukemic activities of combined VPA/cytarabine in pediatric AMLs and suggest that VPA could be an attractive agent for combination therapy of this deadly disease. Based on our results, VPA was recently incorporated into one of the treatment arms for high risk AML in the St. Jude Children’s Research Hospital AML08 clinical trial “A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia”. In this trial, children with AMkL without t(1;22) and other high risk patients without FLT3-ITD will receive a combination of VPA with low dose cytarabine, daunorubicin and etoposide (LD-ADE) during the second induction course. The incorporation of VPA as a new agent for treating high risk AML patients has potential advantages based on its well-characterized toxicity profile and safety in children. Based on our results, incorporation of VPA into cytarabine based clinical trials for treatment of different risk groups of pediatric AML should be strongly considered.
ACKNOWLEDGEMENT

This work was supported by the Karmanos Cancer Institute Start-up Fund, the Children’s Research Center of Michigan, Leukemia Research Life, the Herrick Foundation, the Children’s Leukemia Foundation of Michigan, the National Cancer Institute (CA120772), the Leukemia and Lymphoma Society, the ELANA Fund, Justin’s Gift Charity, the Sehn Family Foundation, St. Baldrick’s Foundation, the Dale Meyer Memorial Endowment for Leukemia Research, the Ring Screw Textron Endowed Chair for Pediatric Cancer Research (J.W.T.), and the Natural Science Foundation of China (NSFC30873093).
REFERENCES


TITLES AND LEGENDS TO FIGURES

Figure 1. Synergistic cytotoxic interactions between VPA and cytarabine toward THP-1 cells. Panel A: THP-1 cells were cultured at 37 °C for 96 h in complete medium with dialyzed fetal bovine serum in 96-well plates at a density of 4 x 10^4 cells/ml, with a range of concentrations of VPA, and viable cell numbers were determined using the MTT reagent and a visible microplate reader. The IC_{50} values were calculated as the concentrations of drug necessary to inhibit 50% proliferation compared to control cells cultured in the absence of drug. The data are presented as mean values ± standard errors from at least 3 independent experiments. Panel B: THP-1 cells were harvested and lysed after incubation with a range of concentrations of VPA (0-8 mM) for 48 h. Soluble proteins were analyzed on Western blots probed by anti-ac-H3, -ac-H4, or -H4 antibody. Panels C: Cytarabine IC_{50}s of THP-1 cells were determined in the absence or presence of VPA treated simultaneously. ** indicates statistically significant difference (p<0.005). Panel D: Standard isobologram analysis of THP-1 cell proliferation inhibition by VPA and cytarabine. The IC_{50} values of each drug are plotted on the axes; the solid line represents the additive effect, while the points represent the concentrations of each drug resulting in 50% inhibition of proliferation. Points falling below the line indicate synergism between drug combinations whereas those falling above the line indicate antagonism. Panel E: In vitro VPA sensitivities of the diagnostic AML blasts were measured by MTT assay, as described in the Materials and Methods. The horizontal lines indicate median VPA IC_{50}s in each group of patient samples. The p value was determined by the nonparametric Mann-Whitney U test. Panel F: Fold decrease of cytarabine IC_{50}s for the diagnostic AML blasts measured by MTT assays in the presence of 0.5 mM or lower VPA compared to that from cytarabine alone. The
horizontal lines indicate the median fold change in each group of patient samples. The $p$ value was determined by the nonparametric Mann-Whitney U test.

**Figure 2. VPA augments apoptosis and S phase arrest induced by cytarabine in pediatric AML cells. Panels A, B, and E:** THP-1 (panel A), Kasumi-1 cells (panel B), and t(8;21) AML diagnostic blasts (panel E) were treated with cytarabine or VPA alone or in combination for 96 h, 96 h, and 24 h, respectively. Early and late apoptosis events in the cells were determined by annexin V/PI staining and flow cytometry analyses. Data are presented as net percent of annexin-V+ cells relative to that of untreated cells. **Panels C&D:** THP-1 (panel C) and Kasumi-1 cells (panel D) were treated with cytarabine or VPA alone or combined for 96 h. Cell cycle distribution was determined by PI staining and flow cytometry analysis.

**Figure 3. Synergistic activation of caspase-9 and caspase-3 by cytarabine and VPA in THP-1 and Kasumi-1 cells.** Whole cell lysates from Kasumi-1 (panels A&B) and THP-1 (panels C&D) cells treated with cytarabine or VPA alone or in combination for 96 h were subjected to caspase-9 and caspase-3 enzymatic assays, respectively, as described in the Materials and Methods. THP-1 and Kasumi-1 cells treated with 500 and 1000 nM daunorubicin, respectively, for 16 h were used as the positive controls.

**Figure 4. Cooperative induction of DNA double strand breaks by VPA and cytarabine in THP-1 and Kasumi-1 cells. Panel A:** Whole cell lysates were prepared from Kasumi-1 (upper
panel) and THP-1 (lower panel) cells treated with VPA and cytarabine alone or in combination for 96 h and subjected to Western blotting probed by anti-γH2AX or -actin antibody. **Panel B:** Kasumi-1 cells were treated with variable concentrations of cytarabine and fixed concentration of VPA or variable concentrations of VPA and fixed concentration of cytarabine alone or in combination for 96 h. Whole cell lysates were extracted and subjected to Western blotting probed by anti-γH2AX or -actin antibody. **Panels C&D:** Kasumi-1 cells were treated with combined cytarabine and VPA for up to 96 h and cell lysates were extracted and subjected to Western blotting probed by anti-γH2AX or –actin antibody (panel C) or to caspase-3 assays as described in the “Methods” (panel D). **Panels E&F:** The relationships between the levels for γH2AX and the activities of caspase-3 in Kasumi-1 cells treated with combined cytarabine and VPA for up to 48 h (panel E) or 96 h (panel F) were determined by the Pearson tests.

**Figure 5. Bim plays a critical role in apoptosis induced by cytarabine and cytarabine plus VPA in pediatric AML cells.** ** Panels A&B:** Kasumi-1 (panel A) and THP-1 (panel B) cells were treated with cytarabine or VPA alone or in combination for 96 h. Whole cell lysates were extracted and subjected to Western blotting probed by anti-Bim, or –actin antibody. **Panel C:** Kasumi-1 and THP-1 cells were treated with combined cytarabine and VPA for up to 96 h and cell lysates were extracted and subjected to Western blotting probed by anti-Bim or –actin antibody. **Panels D&E:** THP-1 cells were infected by Bim or negative (NTC) control shRNA lentivirus clones. After selection with puromycin, infected THP-1 cells were expanded and treated with cytarabine or VPA alone or combined for 96 h. The treated cells were then subjected
to Western blotting for Bim expression (panel C) and to flow cytometry analysis for apoptosis (panel D).
Table 1. Effect of VPA on cytarabine sensitivity in AML cell lines and primary AML blasts

<table>
<thead>
<tr>
<th>Cell line/ Patient</th>
<th>Cytogenetics</th>
<th>VPA IC\textsubscript{50} (mM)</th>
<th>Cytarabine IC\textsubscript{50} (nM)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.0 mM VPA</td>
<td>0.15 mM VPA</td>
</tr>
<tr>
<td>Kasumi-1</td>
<td>45&lt;2n&gt;-X, t(8;21), complex karyotype</td>
<td>0.79±0.03</td>
<td>436.3±41.9</td>
<td>144.7±35.3 (0.522)</td>
</tr>
<tr>
<td>CMS</td>
<td>46, complex karyotype</td>
<td>2.70±0.16</td>
<td>253.5±7.7</td>
<td>ND</td>
</tr>
<tr>
<td>MV4-11</td>
<td>48 (46-48)&lt;2n&gt;XY, t(4;11), complex karyotype</td>
<td>0.37±0.03</td>
<td>106.3±63</td>
<td>23.2±3.4 (0.759)</td>
</tr>
<tr>
<td>THP-1</td>
<td>94 (88-96)&lt;4n&gt;XY/XXY, t(9;11), complex karyotype</td>
<td>2.97±0.10</td>
<td>3328.5±258.4</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 1</td>
<td>46, XX</td>
<td>1.09</td>
<td>14164.0</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 2</td>
<td>46, XY, inv(16)</td>
<td>4.89</td>
<td>6692.0</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 3</td>
<td>46, XY, inv(16)</td>
<td>2.04</td>
<td>3848.0</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 4</td>
<td>46, XY</td>
<td>1.73</td>
<td>2282.0</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 5</td>
<td>46, XY, t(3;5)</td>
<td>0.91</td>
<td>2191.0</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 6</td>
<td>46, XY, +9</td>
<td>1.04</td>
<td>440.3</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 7</td>
<td>46, XY, t(8;21)</td>
<td>0.74</td>
<td>902.4</td>
<td>ND</td>
</tr>
<tr>
<td>Patient 8</td>
<td>46, XX, t(8;21)</td>
<td>0.72</td>
<td>2228.0</td>
<td>306.1 (0.346)</td>
</tr>
<tr>
<td>Patient 9</td>
<td>46, XX, t(8;21)</td>
<td>0.18</td>
<td>495.9</td>
<td>9.177 (0.861)</td>
</tr>
</tbody>
</table>

Note: Cytarabine IC\textsubscript{50} are presented as mean plus standard errors from at least three independent experiments with the cell lines. NA, not applicable; ND, not determined. Numbers in the parentheses represent the combination index (CI) values.
Figure 1A-D

A. VPA alone

B. VPA (mM)

C. VPA + Ara-C

D. Isobologram: Ara-C and VPA

- No VPA
- 0.5 mM VPA + Ara-C
- 1.0 mM VPA + Ara-C

Antagonism

Synergism
Figure 1E&F

E

F

p=0.024

VPA IC_{50} (mM)

Fold-decrease of ara-C IC_{50}

t(8;21) AML
non-t(8;21) AML

t(8;21) AML
non-t(8;21) AML

p=0.024

p=0.024
Figure 2

A

THP-1

Net Annexin V+ cells (%)

900 nM Ara-C
- + - +
0.66 mM VPA
- - + +

B

Kasumi-1

Net Annexin V+ cells (%)

100 nM ara-C
- + - +
0.5 mM VPA
- - + +

C

THP-1

G0/G1
- + - +
S
- - + +
G2/M

D

Kasumi-1

G0/G1
- + - +
S
- - + +
G2/M
Figure 2E

Net Annexin V+ cells (%) vs. 1000 nM Ara-C and 0.5 mM VPA treatments.
Figure 4A&B

A

Kasumi-1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>100 nM Ara-C</th>
<th>0.5 mM VPA</th>
<th>γH2AX</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>100 nM Ara-C</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>0.5 mM VPA</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>γH2AX</td>
<td>1.0</td>
<td>3.4</td>
<td>1.2</td>
<td>5.4</td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

THP-1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>900 nM Ara-C</th>
<th>0.66 mM VPA</th>
<th>γH2AX</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>900 nM Ara-C</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>0.66 mM VPA</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>γH2AX</td>
<td>1.0</td>
<td>1.1</td>
<td>1.3</td>
<td>1.6</td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Kasumi-1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>50 nM Ara-C</th>
<th>100 nM Ara-C</th>
<th>200 nM Ara-C</th>
<th>0.5 mM VPA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>50 nM Ara-C</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>100 nM Ara-C</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>200 nM Ara-C</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>0.5 mM VPA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>γH2AX</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

THP-1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>100 nM Ara-C</th>
<th>0.25 mM VPA</th>
<th>0.50 mM VPA</th>
<th>1.00 mM VPA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>100 nM Ara-C</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>0.25 mM VPA</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>0.50 mM VPA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>1.00 mM VPA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>γH2AX</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 4C-E

C

Kasumi-1, Ara-C + VPA

γH2AX

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>1.5</td>
<td>2.6</td>
</tr>
<tr>
<td>3</td>
<td>3.3</td>
</tr>
<tr>
<td>6</td>
<td>3.5</td>
</tr>
<tr>
<td>12</td>
<td>5.0</td>
</tr>
<tr>
<td>24</td>
<td>8.8</td>
</tr>
<tr>
<td>48</td>
<td>10.1</td>
</tr>
<tr>
<td>96</td>
<td>11.0</td>
</tr>
</tbody>
</table>

β-actin

E

Kasumi-1 (48h)

γH2AX level vs. Caspase-3 activity

r = 0.90, p = 0.006

F

Kasumi-1 (96h)

γH2AX level vs. Caspase-3 activity

r = 0.68, p = 0.06
Figure 5A-C

A

<table>
<thead>
<tr>
<th>Kasumi-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 nM Ara-C 0.5 mM VPA</td>
</tr>
<tr>
<td>-  +  -  +  +</td>
</tr>
<tr>
<td>-  -  +  +  +</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>THP-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>900 nM Ara-C 0.66 mM VPA</td>
</tr>
<tr>
<td>-  +  -  +  +</td>
</tr>
<tr>
<td>-  -  +  +  +</td>
</tr>
</tbody>
</table>

C

Kasumi-1, Ara-C + VPA

<table>
<thead>
<tr>
<th>0 h</th>
<th>1.0</th>
<th>1.1</th>
<th>1.0</th>
<th>1.0</th>
<th>1.1</th>
<th>1.2</th>
<th>1.6</th>
<th>1.9</th>
</tr>
</thead>
</table>

THP-1, Ara-C + VPA

| 0 h  | 1.0  | 1.0  | 1.0  | 1.0  | 1.0  | 1.3  | 2.2  | 2.6  |
Figure 5D&E

**D**

<table>
<thead>
<tr>
<th></th>
<th>NTC-shRNA</th>
<th>Bim-shRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>900 nM Ara-C</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>0.66 mM VPA</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**E**

- **THP-1**

- **NTC-shRNA**
- **Bim-shRNA**

Annexin V+ cells (%)

* 900 nM Ara-C: - + - +
* 0.66 mM VPA: - - + +

**Note:** The figure shows the effects of 900 nM Ara-C and 0.66 mM VPA on THP-1 cells, with NTC-shRNA and Bim-shRNA treatments. The images depict the expression levels of BimEL and β-actin, as well as Annexin V+ cells percentage in response to the treatments.
MECHANISMS OF SYNERGISTIC ANTILEUKEMIC INTERACTIONS BETWEEN VALPROIC ACID AND CYTARABINE IN PEDIATRIC ACUTE MYELOID LEUKEMIA

Chengzhi Xie, Holly Edwards, Xuelian Xu, et al.

Clin Cancer Res Published OnlineFirst October 1, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-1707

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.